Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 15:11:169-174.
doi: 10.33393/grhta.2024.3107. eCollection 2024 Jan-Dec.

Valutazione dell’innovatività e negoziazione di prezzi e rimborso dei farmaci: raccomandazioni da un panel di esperti

[Article in Italian]
Claudio Jommi  1 , Francesca Patarnello  2 , Cosetta Bianchi  3 , Giuliano Buzzetti  3
Affiliations

Valutazione dell’innovatività e negoziazione di prezzi e rimborso dei farmaci: raccomandazioni da un panel di esperti

[Article in Italian]
Claudio Jommi et al. Glob Reg Health Technol Assess. .

Abstract

This paper illustrates the recommendations of a Working Group (WG) on the assessment of drugs innovativeness and the negotiation of price and reimbursement. The WG included researchers, institutions, clinicians, patient representatives and pharmaceutical companies.

The first part of the contribution summarizes the literature on drug pricing models, which was considered in the WG, and, in particular, the pricing criteria, the evaluation and negotiation processes, the management of the uncertainty of the evidence, the use of cross-reference pricing and price negotiation for new indications of existing drugs.

The second part illustrates the results of the WG with a focus on innovativeness assessment, value framework and price negotiation. The main recommendations of the WG are: to define more specific criteria for the identification of comparators and endpoints for macro therapeutic areas/settings; to produce guidelines on the use of indirect comparisons and studies supporting this evidence; to consider the drug value as the main driver of price and reimbursement negotiation; to maintain flexibility in the negotiation process, but, at the same time, to give greater structure and predictability in the assessment of value for money, with a more qualified role of cost-effectiveness and a range of threshold values for the incremental cost-effectiveness ratio; to selectively reintroduce Managed Entry Agreements and the Indication-based pricing model; to implement an early dialogue between the Italian Medicine Agency and the pharmaceutical companies in order to optimize the negotiation process, and a structured involvement of scientific societies and patient representatives.

PubMed Disclaimer

Figures

FIGURA 1 -
FIGURA 1 -
VBP nei maggiori Paesi europei. Fonte: Adattato da Jommi et al. (4). QALY = Quality Adjusted Life Years; ICER = Incremental Cost-Effectiveness Ratio.
See this image and copyright information in PMC

References

    1. Garattini L, Cornago D, De Compadri P. Pricing and reimbursement of in-patent drugs in seven European countries: a comparative analysis. Health Policy. 2007;82(3):330–339. doi: 10.1016/j.healthpol.2006.11.004. - DOI - PubMed
    1. Kleijnen S, Lipska I, Leonardo Alves T et al. Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries. Ann Oncol. 2016;27(9):1768–1775. doi: 10.1093/annonc/mdw233. - DOI - PubMed
    1. Panteli D, Arickx F, Cleemput I et al. Pharmaceutical regulation in 15 European countries review. Health Syst Transit. 2016;18(5):1–122. - PubMed
    1. Jommi C, Armeni P, Costa F, Bertolani A, Otto M. Implementation of Value-based Pricing for Medicines. Clin Ther. 2020;42(1):15–24. doi: 10.1016/j.clinthera.2019.11.006. - DOI - PubMed
    1. Vogler S, Paris V, Ferrario A et al. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries. Appl Health Econ Health Policy. 2017;15(3):307–321. doi: 10.1007/s40258-016-0300-z. - DOI - PubMed

LinkOut - more resources